<b><span style="font-family:Verdana;">Aim</span></b><b><span style="font-family:Verdana;">:</span></b><span style="font-family:;" "...<b><span style="font-family:Verdana;">Aim</span></b><b><span style="font-family:Verdana;">:</span></b><span style="font-family:;" "=""><span style="font-family:Verdana;"> To evaluate photodynamic therapy (PDT) </span><i><span style="font-family:Verdana;">in vitro</span></i><span style="font-family:Verdana;"> to reduce the growth of </span><i><span style="font-family:Verdana;">Candida</span></i><span style="font-family:Verdana;"> spp, and its synergy with the antifungals fluconazole and ketoconazole for inhibition of resistant, DDS and susceptible isolates from asymptomatic carriers and with complicated vulvovaginitis. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> Between 2017 and 2020</span></span><span style="font-family:Verdana;">,</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> we evaluated 230 women with vulvovaginal candidiasis and 400 asymptomatic. We obtained 130 positive cultures for </span><i><span style="font-family:Verdana;">Candida </span></i><span style="font-family:Verdana;">spp from vulvovaginitis and 94 asymptomatic. Yeasts were characterized by classical and molecular tests. Sensitivity to fluconazole and ketoconazole was evaluated by E-test. We used photodynamic light through blue LED, wavelengths between 450 to 470 nm, power of 260 mW, energy</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">f</span><span style="font-family:Verdana;">l</span><span style="font-family:;" "=""><span style="font-family:Verdana;">uence of 270 J/cm</span><sup><span style="font-family:Verdana;">2</span></sup><span style="font-family:Verdana;">, for 15 minutes over all colonies of </span><i><span style="font-family:Verdana;">Candida</span></i><span style="font-family:Verdana;"> spp</span></span><span style="font-family:Verdana;">. </span><span style="font-family:Verdana;">Methylene blue (MB) at 450 mg/mL, 2% gentian violet (VG) and 50</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">μM curcumin (CR) were used in association or not with LED irradiation. Suspensions of </span><i><span style="font-family:Verdana;">Candida </span></i><span style="font-family:Verdana;">spp of 10</span><sup><span style="font-family:Verdana;">6</span></sup><span style="font-family:Verdana;"> CFU/mL, subjected to the different assays, were introduced in 96-well microplates, incubated for 48 hours at 35</span></span><span style="font-family:Verdana;"><span style="white-space:nowrap;">˚</span>C and the readings at 530</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">nm. The samples were finally cultivated in Petri plates containing Sabouraud dextrose agar to assess the growth inhibition. All procedures were in triplicate. </span><b><span style="font-family:Verdana;">Results:</span></b> <i><span style="font-family:Verdana;">C. albicans</span></i><span style="font-family:Verdana;"> was prevalent in vulvovaginal candidiasis, however, we also isolated non-</span><i><span style="font-family:Verdana;">albicans</span></i><span style="font-family:Verdana;"> species such as </span><i><span style="font-family:Verdana;">C. glabrata</span></i><span style="font-family:Verdana;">,</span><i><span style="font-family:Verdana;"> C. tropicalis</span></i><span style="font-family:Verdana;"> and </span><i><span style="font-family:Verdana;">C. parapsilosis</span></i><span style="font-family:Verdana;">. There was a substantial reduction (66.6% to 83.8%) of the CFU/mL of the isolates treated with FDT. Gentian violet at 2% alone reduced the growth of CFU/ml of </span><i><span style="font-family:Verdana;">Candida</span></i><span style="font-family:Verdana;"> spp from 69% to 75%. Among isolates of vaginitis and asymptomatic carriers, after using FDT, we found a reduction in resistant phenotypes and DDS for fluconazole in percentages from 20% to 100% for </span><i><span style="font-family:Verdana;">C. albicans</span></i><span style="font-family:Verdana;">, from 50% to 100% </span><i><span style="font-family:Verdana;">C. glabrata</span></i><span style="font-family:Verdana;">, 33.3% to 100% </span><i><span style="font-family:Verdana;">C. parapsilosis</span></i><span style="font-family:Verdana;"> and 100% </span><i><span style="font-family:Verdana;">C. tropicalis</span></i><span style="font-family:Verdana;">. For ketoconazole in the same isolates, there was a reduction in phenotypes with MIC</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">></span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">16 μg/mL of up to 50% in </span><i><span style="font-family:Verdana;">C. albicans</span></i><span style="font-family:Verdana;">, 50% to 100% </span><i><span style="font-family:Verdana;">C. glabrata</span></i><span style="font-family:Verdana;">, 50% to 100% </span><i><span style="font-family:Verdana;">C. tropicalis</span></i><span style="font-family:Verdana;">. </span><b><span style="font-family:Verdana;">Conclusions:</span></b><span style="font-family:Verdana;"> PDT with MB, GV and CR revealed efficacy </span><i><span style="font-family:Verdana;">in vitro </span></i><span style="font-family:Verdana;">in reducing the growth of </span><i><span style="font-family:Verdana;">C. albicans</span></i><span style="font-family:Verdana;"> and non-</span><i><span style="font-family:Verdana;">albicans</span></i><span style="font-family:Verdana;">, especially due to chronic recurrent vulvovaginitis.</span></span>展开更多
文摘<b><span style="font-family:Verdana;">Aim</span></b><b><span style="font-family:Verdana;">:</span></b><span style="font-family:;" "=""><span style="font-family:Verdana;"> To evaluate photodynamic therapy (PDT) </span><i><span style="font-family:Verdana;">in vitro</span></i><span style="font-family:Verdana;"> to reduce the growth of </span><i><span style="font-family:Verdana;">Candida</span></i><span style="font-family:Verdana;"> spp, and its synergy with the antifungals fluconazole and ketoconazole for inhibition of resistant, DDS and susceptible isolates from asymptomatic carriers and with complicated vulvovaginitis. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> Between 2017 and 2020</span></span><span style="font-family:Verdana;">,</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> we evaluated 230 women with vulvovaginal candidiasis and 400 asymptomatic. We obtained 130 positive cultures for </span><i><span style="font-family:Verdana;">Candida </span></i><span style="font-family:Verdana;">spp from vulvovaginitis and 94 asymptomatic. Yeasts were characterized by classical and molecular tests. Sensitivity to fluconazole and ketoconazole was evaluated by E-test. We used photodynamic light through blue LED, wavelengths between 450 to 470 nm, power of 260 mW, energy</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">f</span><span style="font-family:Verdana;">l</span><span style="font-family:;" "=""><span style="font-family:Verdana;">uence of 270 J/cm</span><sup><span style="font-family:Verdana;">2</span></sup><span style="font-family:Verdana;">, for 15 minutes over all colonies of </span><i><span style="font-family:Verdana;">Candida</span></i><span style="font-family:Verdana;"> spp</span></span><span style="font-family:Verdana;">. </span><span style="font-family:Verdana;">Methylene blue (MB) at 450 mg/mL, 2% gentian violet (VG) and 50</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">μM curcumin (CR) were used in association or not with LED irradiation. Suspensions of </span><i><span style="font-family:Verdana;">Candida </span></i><span style="font-family:Verdana;">spp of 10</span><sup><span style="font-family:Verdana;">6</span></sup><span style="font-family:Verdana;"> CFU/mL, subjected to the different assays, were introduced in 96-well microplates, incubated for 48 hours at 35</span></span><span style="font-family:Verdana;"><span style="white-space:nowrap;">˚</span>C and the readings at 530</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">nm. The samples were finally cultivated in Petri plates containing Sabouraud dextrose agar to assess the growth inhibition. All procedures were in triplicate. </span><b><span style="font-family:Verdana;">Results:</span></b> <i><span style="font-family:Verdana;">C. albicans</span></i><span style="font-family:Verdana;"> was prevalent in vulvovaginal candidiasis, however, we also isolated non-</span><i><span style="font-family:Verdana;">albicans</span></i><span style="font-family:Verdana;"> species such as </span><i><span style="font-family:Verdana;">C. glabrata</span></i><span style="font-family:Verdana;">,</span><i><span style="font-family:Verdana;"> C. tropicalis</span></i><span style="font-family:Verdana;"> and </span><i><span style="font-family:Verdana;">C. parapsilosis</span></i><span style="font-family:Verdana;">. There was a substantial reduction (66.6% to 83.8%) of the CFU/mL of the isolates treated with FDT. Gentian violet at 2% alone reduced the growth of CFU/ml of </span><i><span style="font-family:Verdana;">Candida</span></i><span style="font-family:Verdana;"> spp from 69% to 75%. Among isolates of vaginitis and asymptomatic carriers, after using FDT, we found a reduction in resistant phenotypes and DDS for fluconazole in percentages from 20% to 100% for </span><i><span style="font-family:Verdana;">C. albicans</span></i><span style="font-family:Verdana;">, from 50% to 100% </span><i><span style="font-family:Verdana;">C. glabrata</span></i><span style="font-family:Verdana;">, 33.3% to 100% </span><i><span style="font-family:Verdana;">C. parapsilosis</span></i><span style="font-family:Verdana;"> and 100% </span><i><span style="font-family:Verdana;">C. tropicalis</span></i><span style="font-family:Verdana;">. For ketoconazole in the same isolates, there was a reduction in phenotypes with MIC</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">></span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">16 μg/mL of up to 50% in </span><i><span style="font-family:Verdana;">C. albicans</span></i><span style="font-family:Verdana;">, 50% to 100% </span><i><span style="font-family:Verdana;">C. glabrata</span></i><span style="font-family:Verdana;">, 50% to 100% </span><i><span style="font-family:Verdana;">C. tropicalis</span></i><span style="font-family:Verdana;">. </span><b><span style="font-family:Verdana;">Conclusions:</span></b><span style="font-family:Verdana;"> PDT with MB, GV and CR revealed efficacy </span><i><span style="font-family:Verdana;">in vitro </span></i><span style="font-family:Verdana;">in reducing the growth of </span><i><span style="font-family:Verdana;">C. albicans</span></i><span style="font-family:Verdana;"> and non-</span><i><span style="font-family:Verdana;">albicans</span></i><span style="font-family:Verdana;">, especially due to chronic recurrent vulvovaginitis.</span></span>